Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BioPharma CreditLSE:BPCR +1.45%51 EV-to-OCF is 11.96 as of Aug. 17, 2026, which is 24% above its 10-year median of 9.61. GuruFocus rates LSE:BPCR with a GF Score™ of 51/100 and a GF Value™ of $0.96 (Fairly Valued). The stock has 2 warning signs investors should review. Among 1,506 Asset Management companies, BioPharma Credit ranks worse than 64.48% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, BioPharma Credit's Enterprise Value is $1,089.4 Mil.
BioPharma Credit's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $91.1 Mil. Therefore, BioPharma Credit's EV-to-OCF for today is 11.96.
The historical rank and industry rank for BioPharma Credit's EV-to-OCF or its related term are showing as below:
LSE:BPCR'
s EV-to-OCF Range Over the Past 10 Years
Min: 5.39 Med: 9.61 Max: 20.33
Current: 11.96
During the past 9 years, the highest EV-to-OCF of BioPharma Credit was 20.33. The lowest was 5.39. And the median was 9.61.
LSE:BPCR's EV-to-OCF is ranked worse than 64.48% of 1506
companies
in the Asset Management industry
Industry Median: 5.85
vs LSE:BPCR: 11.96
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
BioPharma Credit's PE Ratio (TTM) for today is calculated as:
BioPharma Credit's share price for today is $0.982.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioPharma Credit's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.114.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
BioPharma Credit EV-to-OCF Related Terms
BioPharma Credit EV-to-OCF Historical Data
* Premium members only.
The historical data trend for BioPharma Credit's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Asset Management subindustry, BioPharma Credit's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
BioPharma Credit EV-to-OCF vs Asset Management Industry
For the Asset Management industry and Financial Services sector, BioPharma Credit's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where BioPharma Credit's EV-to-OCF falls into.
BioPharma Credit's current Enterprise Value is $1,089.4 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. BioPharma Credit's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $91.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BioPharma Credit (LSE:BPCR) has a EV-to-OCF of 11.96 as of Aug. 17, 2026. This is 24% above median its historical median of 9.61. Over the past decade, BioPharma Credit's EV-to-OCF has ranged from 5.39 to 20.33. According to the industry distribution chart, BioPharma Credit ranks #971 out of 1506 companies in the Asset Management industry, placing it in the top 64.5%.
Is BioPharma Credit's EV-to-OCF too high?
BioPharma Credit's current EV-to-OCF of 11.96 is 24% above median its 10-year median of 9.61. Over the past 10 years, this metric has ranged from a low of 5.39 to a high of 20.33. The Asset Management industry median EV-to-OCF is 5.85. BioPharma Credit's value of 11.96 is 104.4% above this industry median. Based on the distribution chart, BioPharma Credit ranks #971 out of 1506 companies in the Asset Management industry, which is below the industry midpoint. Overall, BioPharma Credit has a GF Score™ of 51/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does BioPharma Credit's EV-to-OCF compare to BLK and BX?
According to the Asset Management industry distribution chart, BioPharma Credit ranks #971 out of 1506 companies for EV-to-OCF. This places BioPharma Credit in the lower half of its industry. The industry median EV-to-OCF is 5.85. BioPharma Credit's value of 11.96 is 104.4% above this benchmark. Historically, BioPharma Credit's own EV-to-OCF has ranged from 5.39 to 20.33 over the past decade. While the company's 10-year median is 9.61 vs. the industry median of 5.85, BioPharma Credit has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for an Asset Management company?
The median EV-to-OCF among Asset Management companies is 5.85, based on 1,506 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. BioPharma Credit's current EV-to-OCF of 11.96 is 104.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Asset Management industry, the median EV-to-OCF is 5.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. BioPharma Credit's current EV-to-OCF is 11.96, which is 24% above median its own 10-year median of 9.61. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is BioPharma Credit stock overvalued right now?
Based on GuruFocus' analysis, BioPharma Credit (LSE:BPCR) is currently considered Fairly Valued. The stock's GF Value™ is $0.96, compared to a current price of $0.98 — trading 2.3% above its estimated fair value. The current EV-to-OCF is 11.96, which is 24% above median its 10-year median of 9.61 and 104.4% above the Asset Management industry median of 5.85. BioPharma Credit's overall GF Score™ is 51/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For BioPharma Credit (LSE:BPCR), the current EV-to-OCF is 11.96 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is BioPharma Credit (LSE:BPCR) Overvalued in 2026?
Based on GuruFocus' analysis, BioPharma Credit stock appears to be overvalued.
The current stock price of $0.98 is trading 2.3% above its estimated GF Value™ of $0.96.
GuruFocus considers BioPharma Credit to be Fairly Valued.
Key valuation signals for LSE:BPCR:
EV-to-OCF: 11.96 (24% above median its 10-year median of 9.61)
GF Value™: $0.96 vs. price of $0.98 (2.3% above fair value)
Industry Position: 104.4% above the Asset Management median (#971 of 1506)
No single metric tells the full story. See the LSE:BPCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioPharma Credit PLC is an investment trust. Its investment objective is to generate long-term shareholder returns predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The trust focuses on achieving its investment objective through direct or indirect exposure to debt assets, which include royalty investments, senior secured debt, unsecured debt, and credit linked notes. Its diversified investment portfolio is mainly secured by approved life sciences products and the cash flows derived from their sales.
51GF Score
Get the complete analysis for LSE:BPCR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LSE:BPCR has been successfully added to your 
